Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
$2.40
+0.8%
$1.90
$0.80
$3.42
$98.59M-0.88171,843 shs41,063 shs
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
$6.20
+1.1%
$5.95
$4.65
$10.24
$103.73M0.2674,116 shs38,667 shs
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
$9.59
+7.0%
$8.54
$4.64
$61.89
$117.53M3.2189,076 shs154,112 shs
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
$0.36
+10.1%
$0.34
$0.25
$0.48
$30.83M1.48913,992 shs214,616 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
+0.42%-9.85%+43.37%+142.86%+20.20%
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
-0.33%-4.67%0.00%+7.73%+16.10%
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
+3.34%+0.67%+8.34%+27.27%-82.90%
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
-2.25%-1.14%-8.68%+15.67%-14.09%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
2.1989 of 5 stars
3.33.00.00.02.81.70.0
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
2.0359 of 5 stars
3.53.00.00.02.30.80.0
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
4.3078 of 5 stars
3.63.00.04.72.82.50.0
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
1.7511 of 5 stars
3.50.00.00.01.91.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
2.50
Moderate Buy$5.50129.17% Upside
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
3.00
Buy$16.50166.13% Upside
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
3.10
Buy$49.00410.95% Upside
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
3.00
Buy$3.88979.39% Upside

Current Analyst Ratings Breakdown

Latest IGC, CRBP, ANEB, and COYA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/13/2025
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00
8/13/2025
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00
8/6/2025
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$56.00 ➝ $53.00
7/30/2025
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$28.00
7/24/2025
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00
7/23/2025
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/12/2025
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/9/2025
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$16.00
7/1/2025
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00
6/9/2025
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00
5/15/2025
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$6.00 ➝ $3.00
(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/AN/AN/AN/A$0.15 per shareN/A
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
$3.55M29.22N/AN/A$2.37 per share2.62
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
N/AN/AN/AN/A$9.06 per shareN/A
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
$1.27M25.65N/AN/A$0.08 per share4.49
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
-$8.20M-$0.26N/AN/AN/A-90.11%-84.53%9/24/2025 (Estimated)
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
-$14.88M-$1.07N/AN/AN/AN/A-48.88%-43.32%N/A
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
-$40.21M-$4.76N/AN/AN/AN/A-43.65%-39.62%N/A
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
-$13M-$0.08N/AN/AN/A-714.16%-122.44%-88.40%N/A

Latest IGC, CRBP, ANEB, and COYA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
-$0.22-$0.36-$0.14-$0.36$0.78 million$0.16 million
8/5/2025Q2 2025
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
-$1.55-$1.44+$0.11-$1.44N/AN/A
5/13/2025Q3 2025
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
-$0.05-$0.04+$0.01-$0.04N/AN/A
5/13/2025Q1 2025
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
-$0.44-$0.44N/A-$0.44$2.63 million$257.88 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/AN/AN/AN/AN/A
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
N/AN/AN/AN/AN/A
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
N/AN/AN/AN/AN/A
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/A
25.29
25.29
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
N/A
8.84
8.84
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
N/A
9.21
9.21
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
0.02
1.15
0.98

Institutional Ownership

CompanyInstitutional Ownership
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
28.40%
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
39.75%
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
64.64%
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
3.87%

Insider Ownership

CompanyInsider Ownership
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
80.60%
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
12.00%
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
4.00%
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
31.48%
CompanyEmployeesShares OutstandingFree FloatOptionable
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
441.08 million7.97 millionNot Optionable
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
616.73 million14.72 millionNot Optionable
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
4012.26 million11.77 millionOptionable
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
6190.81 million54.60 millionN/A

Recent News About These Companies

IGC Pharma highlights preclinical data on IGC-M3
IGC Pharma Inc Trailing Returns - Morningstar
Insights Ahead: IGC Pharma's Quarterly Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Anebulo Pharmaceuticals stock logo

Anebulo Pharmaceuticals NASDAQ:ANEB

$2.40 +0.02 (+0.84%)
Closing price 04:00 PM Eastern
Extended Trading
$2.38 -0.02 (-0.63%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Coya Therapeutics stock logo

Coya Therapeutics NASDAQ:COYA

$6.20 +0.07 (+1.14%)
Closing price 04:00 PM Eastern
Extended Trading
$6.19 -0.01 (-0.16%)
As of 06:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Corbus Pharmaceuticals stock logo

Corbus Pharmaceuticals NASDAQ:CRBP

$9.59 +0.63 (+7.03%)
Closing price 04:00 PM Eastern
Extended Trading
$9.54 -0.04 (-0.47%)
As of 05:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

IGC Pharma stock logo

IGC Pharma NYSEMKT:IGC

$0.36 +0.03 (+10.09%)
Closing price 03:58 PM Eastern
Extended Trading
$0.36 +0.00 (+0.28%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.